| Names | |
|---|---|
| Preferred IUPAC name 2,4,6-Tripropyl-1,3,5,2λ5,4λ5,6λ5-trioxatriphosphinane-2,4,6-trione | |
| Other names PPACA; PPAA; T3P; Propylphosphonic anhydride | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| ECHA InfoCard | 100.102.078 |
| EC Number |
|
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C9H21O6P3 | |
| Molar mass | 318.182 g·mol−1 |
| Hazards | |
| GHS labelling: | |
| | |
| Warning | |
| H290, H314 | |
| P234, P260, P264, P280, P301+P330+P331, P303+P361+P353, P304+P340, P305+P351+P338, P310, P321, P363, P390, P404, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Propanephosphonic acid anhydride (PPAA, T3P) is the trimeric anhydride of n-propylphosphonic acid. It is a useful reagent for peptide synthesis reactions, where it activates the carboxylic acid partner for subsequent reaction with a primary or secondary amine. [1] It is commercially available as 50% solution in DMF or ethyl acetate as a slightly yellow mixture. [2] [3]
Examples of T3P being used in the industrial syntheses of pharmaceuticals include the Pfizer synthesis of dacomitinib, the Neurosearch synthesis of SNDRIs such as PC44156003, [4] the last step of the synthesis of selinexor, [5] and the synthesis of darolutamide. [5]